TSON TranS1 Inc. featured news, full reports, and detailed charts
TranS1 Inc. (TSON) Wrap Up:
We are a medical device company focused on designing, developing and marketing products that implement our proprietary minimally invasive surgical approach to treat degenerative disc disease affecting the lower lumbar region of the spine. Using this TranS1 approach, a surgeon can access discs in the lower lumbar region of the spine through a 1.5 cm incision adjacent to the tailbone and can perform an entire fusion procedure through a small tube that provides direct access to the degenerative disc. We developed our TranS1 approach to allow spine surgeons to access and treat degenerative lumbar discs without compromising important surrounding soft tissue. We believe this approach enables fusion procedures to be performed with low complication rates, short procedure times, low blood loss, short hospital stays, fast recovery times and reduced pain. We have developed and currently market in the United States and Europe two single-level fusion products, AxiaLIF and AxiaLIF 360°. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f25%2f0000950144-08-002267.html#FIS_BUSINESS"TranS1, Inc. (TSON:NASDAQ)
Snapshot of TranS1, Inc. (TSON)
|
OPEN
--
|
PREVIOUS CLOSE
$3.72
|
|
|
DAY HIGH
--
|
DAY LOW
--
|
|
|
52 WEEK HIGH
05/29/09 - $8.74
|
52 WEEK LOW
11/2/09 - $3.62
|
|
|
MARKET CAP
76.8M
|
AVERAGE VOLUME 3 mo
49.4K
|
|
|
DILUTED EPS TTM
$-1.07
|
SHARES OUTSTANDING
20.6M
|
|
|
TSON Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
TSON Top Compensated Officers
Executives, Board Directors
Key developments for TranS1, Inc. (TSON)
TranS1 Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported revenues of $6.9 million, representing a 15% increase over revenues of $6.0 million in the third quarter of 2008. Net loss was $5.6 million and $4.8 million for the quarters ended September 30, 2009 and 2008, respectively. GAAP net loss per common share was $0.27 in the third quarter of 2009 compared to a net loss per share of $0.23 in the third quarter of 2008. Operating loss was $5.6 million compared to $5.4 million for the same period of last year. Non-GAAP net loss was $5 million or $0.24 per diluted share compared to net loss of $4.0 million or $0.20 per diluted share for the same period of last year. For the nine months, the company reported net loss of $17.5 million or $0.85 per diluted share on revenue of $23.5 million compared to net loss of $12.5 million or $0.62 per diluted share on revenue of $18 million for the same period of last year. Operating loss was $17.9 million compared to $14.7 million for the same period of last year. Non-GAAP net loss was $15.3 million or $0.74 per diluted share compared to net loss of $9.9 million or $0.49 per diluted share for the same period of last year.
TranS1, Inc. expected to Report Fiscal Year 2009 Results on February 22, 2010. This event was calculated by Capital IQ (Created on October 29, 2009).
TranS1, Inc., Q3 2009 Earnings Call, Oct 29 2009
TSON Competitors
| Company | Last | Change |
| Alphatec Holdings Inc | $4.42 USD | 0.00 |
| NuVasive Inc | $37.15 USD | 0.00 |
| Zimmer Holdings Inc | $56.86 USD | 0.00 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | TSON | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 2.5x |
|
| Price/Book | 1.1x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 0.5x |
|
|
TSON |
||
TSON transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||